ABOUT THE RESEARCHER

OVERVIEW

Dr. Son’s research focuses on Kawasaki disease and childhood Systemic Lupus Erythematosus. She is also actively involved with the Kawasaki Disease Biorepository.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Mistaken MIS-C: A Case Series of Bacterial Enteritis Mimicking MIS-C. Pediatr Infect Dis J. 2021 04 01; 40(4):e159-e161. View abstract
  2. Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms. Pediatr Rheumatol Online J. 2021 Mar 17; 19(1):31. View abstract
  3. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021 03 16; 325(11):1074-1087. View abstract
  4. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol. 2021 Mar 05. View abstract
  5. Detailed Assessment of Left Ventricular Function in Multisystem Inflammatory Syndrome in Children Using Strain Analysis. CJC Open. 2021 Feb 25. View abstract
  6. Socioeconomic and Racial/Ethnic Disparities in Multisystem Inflammatory Syndrome. Pediatrics. 2021 Feb 18. View abstract
  7. Reply to Prophylactic Anticoagulation: Comment on the ACR Guidance for Management of Multisystem Inflammatory Syndrome in Children. Arthritis Rheumatol. 2021 Feb 14. View abstract
  8. Multiple Emergency Department Visits for a Diagnosis of Kawasaki Disease: An Examination of Risk Factors and Outcomes. J Pediatr. 2021 Jan 13. View abstract
  9. Development of a Set of Lupus-Specific, Ambulatory Care-Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study. Arthritis Care Res (Hoboken). 2021 01; 73(1):146-157. View abstract
  10. Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES). Child Neurol Open. 2020 Jan-Dec; 7:2329048X20979253. View abstract
  11. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2020 Dec 05. View abstract
  12. Early Features of Progressive Hemifacial Atrophy-Clinical and Imaging Findings. JAMA Dermatol. 2020 12 01; 156(12):1376-1379. View abstract
  13. High-Throughput Screening of Kawasaki Disease Sera for Antiviral Antibodies. J Infect Dis. 2020 11 09; 222(11):1853-1857. View abstract
  14. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View abstract
  15. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. Arch Dis Child. 2021 03; 106(3):247-252. View abstract
  16. Atrioventricular Block in Children With Multisystem Inflammatory Syndrome. Pediatrics. 2020 11; 146(5). View abstract
  17. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr. 2021 Feb; 180(2):307-322. View abstract
  18. Chronic chest pain: Where is the pathology? Pediatr Pulmonol. 2020 11; 55(11):3145-3151. View abstract
  19. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020 07 23; 383(4):334-346. View abstract
  20. Pediatric inflammatory syndrome temporally related to covid-19. BMJ. 2020 06 03; 369:m2123. View abstract
  21. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest. 2020 04 01; 130(4):1669-1682. View abstract
  22. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020 03 26; 5(6). View abstract
  23. Multicentre validation of a computer-based tool for differentiation of acute Kawasaki disease from clinically similar febrile illnesses. Arch Dis Child. 2020 08; 105(8):772-777. View abstract
  24. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020 02; 79(2):225-231. View abstract
  25. Impact of Socioeconomic Status on Outcomes of Patients with Kawasaki Disease. J Pediatr. 2019 09; 212:87-92. View abstract
  26. A Case Report of Takayasu's Arteritis and Ulcerative Colitis in a Pediatric Patient with Chronic Recurrent Multifocal Osteomyelitis Successfully Treated with Infliximab: Diagnostic Clues in Disease Associations and Immune Dysregulation. Case Rep Rheumatol. 2019; 2019:8157969. View abstract
  27. Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population. J Am Heart Assoc. 2019 06 04; 8(11):e011319. View abstract
  28. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. Pediatrics. 2019 06; 143(6). View abstract
  29. Kawasaki Disease. Pediatr Rev. 2018 Feb; 39(2):78-90. View abstract
  30. Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline z Scores. J Am Heart Assoc. 2017 May 31; 6(6). View abstract
  31. Evidence-based decision support for pediatric rheumatology reduces diagnostic errors. Pediatr Rheumatol Online J. 2016 Dec 13; 14(1):67. View abstract
  32. Disease activity and transition outcomes in a childhood-onset systemic lupus erythematosus cohort. Lupus. 2016 Nov; 25(13):1431-1439. View abstract
  33. The presentation and management of granulomatosis with polyangiitis (Wegener's Granulomatosis) in the pediatric airway. Laryngoscope. 2017 01; 127(1):233-240. View abstract
  34. Laryngeal sarcoidosis: presentation and management in the pediatric population. Int J Pediatr Otorhinolaryngol. 2015 Sep; 79(9):1382-7. View abstract
  35. Intra-articular glucocorticoid injections in patients with juvenile idiopathic arthritis in a Singapore hospital. Singapore Med J. 2014 May; 55(5):248-52. View abstract
  36. A85: effect of childhood-onset systemic lupus erythematosus on linear height and body mass index. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S118. View abstract
  37. Outcomes in hospitalized pediatric patients with systemic lupus erythematosus. Pediatrics. 2014 Jan; 133(1):e106-13. View abstract
  38. Hypergammaglobulinemia in the pediatric population as a marker for underlying autoimmune disease: a retrospective cohort study. Pediatr Rheumatol Online J. 2013 Nov 01; 11(1):42. View abstract
  39. Kawasaki disease. Pediatr Rev. 2013 Apr; 34(4):151-62. View abstract
  40. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. J Rheumatol. 2013 Mar; 40(3):273-81. View abstract
  41. Multiple juvenile idiopathic arthritis subtypes demonstrate proinflammatory IgG glycosylation. Arthritis Rheum. 2012 Sep; 64(9):3025-33. View abstract
  42. Management of Kawasaki disease: corticosteroids revisited. Lancet. 2012 Apr 28; 379(9826):1571-2. View abstract
  43. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011 Feb; 63(2):545-55. View abstract
  44. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011 Apr; 158(4):644-649.e1. View abstract
  45. Musculoskeletal causes of pediatric chest pain. Pediatr Clin North Am. 2010 Dec; 57(6):1385-95. View abstract
  46. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2010 Nov 4. View abstract
  47. Kawasaki Disease. Nelson Textbook of Pediatrics. 2010. View abstract
  48. Essentials of Emergency Medicine. Rheumatologic Emergencies. 2010. View abstract
  49. Juvenile Arthritis. Targeted Treatment of the Rheumatic Diseases. 2010; 70-82. View abstract
  50. Kawasaki Disease. Rudolph's Pediatrics. 2010. View abstract
  51. Pocket Pediatrics. Juvenile Rheumatoid Arthritis, Kawsaki Disease, Lyme Disease, Serum Sickness, Systemic Lupus Erythematosus. 2010. View abstract
  52. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009 Jul; 124(1):1-8. View abstract
  53. The Boston Marathon Study: a novel approach to research during residency. Pediatrics. 2006 May; 117(5):1818-22. View abstract